Objectives: The aim of this study was to establish the prevalence of intraductal papillary mucinous neoplasms (IPMNs) without and with highrisk stigmata (HRS)/worrisome features (WF) and the epidemiologic association between IPMNs and other diseases.
T he incidental discovery of an asymptomatic intraductal papillary mucinous neoplasm (IPMN) represents one of the most important challenges of the "clinical pancreatologist" because it is a precancerous lesion that can evolve into carcinoma as colorectal polyps. Thus, knowledge of its true prevalence in the general population is a key point of this pathology. [1] [2] [3] [4] [5] In fact, preliminary reliable data [3] [4] [5] regarding the prevalence rate (approximately 2.5% in the adult population) put IPMNs in the group of "modern and technologic" epidemic disease, a potentially early expression of invasive cancer as are pulmonary nodules (8.5%) 6 or colorectal polyps (7%). 7 At the same time, the high prevalence of IPMNs could represent an opportunity for the early diagnosis of pancreatic cancer, 8, 9 but it could also be a costly and worthless use of health care system resources. 10, 11 The study was conducted including outpatients who were referred to a western tertiary hospital (S. Orsola-Malpighi, Bologna, Italy) for elective abdominal ultrasound (US) examination. The primary end point was to establish the prevalence rate of IPMNs in a nonselected population. The secondary end points were to establish the prevalence rate of high-risk stigmata (HRS)/worrisome features (WF) IPMNs and to evaluate the epidemiologic association between IPMNs and many other types of neoplasms or chronic inflammatory diseases.
MATERIALS AND METHODS
With the approval of the Ethics Committee of S. OrsolaMalpighi Hospital and patient informed consent, US examinations performed on outpatients, prospectively collected from January 2012 to December 2015 at the Ultrasound Service of S. Orsola-Malpighi Hospital, were reviewed. The exclusion criteria were (1) age younger than 18 years, (2) history of pancreatic disease, (3) symptoms of pancreatic disease, and (4) no additional examination with magnetic resonance imaging (MRI) confirming and characterizing pancreatic cyst lesions (PCLs). The details of the US examinations are reported in the Supplemental Methods, http://links.lww.com/MPA/A695. For each subject included in the analysis, the following parameters were extracted: presence and type of PCLs, age, sex, reason for abdominal US (follow-up or no specific reason), personal history of solid or blood neoplasms, and personal history of chronic diseases. The following parameters were also reported in patients with PCLs: size of cyst in mm (in cases of multiple cysts, the diameter of the largest cyst was considered), site of the lesion (head, body-tail or diffuse), the presence of mural nodules, Wirsung duct size in millimeters, and the presence of a thickened enhancing wall. Initially, beginning with the assumption that abdominal US has a sensitivity approximately the same as a computed tomography (CT) scan, the PCL prevalence rate was calculated. The crude prevalence rate of the PCLs was considered plausible based on the data previously reported by Zanini et al. 3 In fact, if the prevalence rate of our cohort was inferior to that reported by Zanini et al 3 using CT scan, the sensitivity of the US may have been low regarding additional speculation regarding the IPMN prevalence rates. Subsequently, the primary and secondary end points were the IPMN and HRS/WF IPMN prevalence rates, respectively. The HRS and WF were defined according to the radiological signs reported in the Fukuoka international consensus. 12, 13 All prevalence rates were calculated as both crude and standardized rates. The crude prevalence rate was defined as the ratio between the total number of outpatients who received a confirmed diagnosis of PCLs, IPMN, or HRS/WF IPMN using MRI at a given time and the overall number of outpatients in the study. On the contrary, the standardized prevalence was obtained using the method of direct standardization 14 for age and sex. Briefly, in our setting, this approach was required because, although the specific prevalence rate for each class of age and sex was known, the population in the study did not represent the distribution of the general population for age and sex. Thus, the crude prevalence was standardized in 2 ways: using the Italian population and by using the European Standardized population (ESP2013). 15 Finally, the other secondary end point was calculated using univariate and multivariate logistic regression. The nonnegligible association between the covariates (age, sex, diseases) and the presence of IPMNs was explored. The results, together with their 95% confidence intervals (CIs), were reported, and 2-tailed P < 0.05 was considered statistically significant.
RESULTS
During the observation period, 10,345 abdominal USs were performed. After the selection process, 6353 outpatients were included in the study and were analyzed (Fig. 1) Regarding the primary end point, Table 1 shows that the crude prevalence rate of IPMNs in our cohort of patients was 3.4% (220/6353). In addition, the crude prevalence rate was stratified by age group: 0%, 0.5%, 0.2%, 1.0%, 3.0%, 3.8%, 7.2%, and 10.8% in age groups 19.9 years or younger, 20 to 29.9, 30 to 39.9, 40 to 49.9, 50 to 59.9, 60 to 69.9, 70 to 79.9, and 80 years or older, respectively. When the distribution for the age of the Italian population was applied, a total of 1,531,264 IPMNs were expected with a standardized prevalence rate of 2.5%. When the standardization was conducted using the European Standard Population (ESP2013), the adjusted prevalence rate was 2.3%, with 2257 IPMNs expected per 100,000 residents. Table 2 shows the prevalence rates stratified by age and sex. In our cohort of patients, the crude prevalence rate in the male population was 2.1% with 0%, 0.5%, 0%, 0%, 1.9%, 2.8%, 4.0%, and 6.4% in age groups 19.9 years or younger, 20 to 29.9, 30 to 39.9, 40 to 49.9, 50 to 59.9, 60 to 69.9, 70 to 79.9, and 80 years or older, respectively. The standardized crude prevalence rate according to the male Italian and European populations was 1.3%, with 391,841 and 1319 asymptomatic IPMNs expected, respectively. Regarding the female population, the crude prevalence rate was 4.8% with 0%, 0.5%, 0.3%, 1.9%, 4.1%, 4.7%, 9.09%, and 14.4% in age groups 19.9 years or younger, 20 to 29.9, 30 to 39.9, 40 to 49.9, 50 to 59.9, 60 to 69.9, 70 to 79.9, and 80 years or older, respectively. When the Italian population was used, a total of 1,163,853 IPMNs were expected with a standardized prevalence The European standard population was an artificial population structure created using an average projection of the population of the member states for 2011-2030 (ESP2013). ‡
The European standard population assumed that the male-to-female ratio is 1:1.
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The European standard population assumed that the male-to-female ratio is 1:1. Regarding secondary end points, the crude and standardized prevalence rates of HRS/WF IPMNs are reported in Table 3 . In our population, the crude prevalence rates were 0.3% and 0.7% in the male and female populations, respectively, whereas it reached 0.5% in the overall population. The age-adjusted crude prevalence rates were equal to 0% until 50 and 40 years of age in the male and female populations, respectively. In the male population, the presence of HRS/WF IPMNs was 0.1%, 0.2%, 0.2%, and 2.9% in age groups 50 to 59.9, 60 to 69.9, 70 to 79.9, and 80 years or older, respectively. In the female population, the presence of HRS/WF IPMNs was 0.2%, 0.4%, 1.0%, 1.7%, and 1.4% in age groups 40 to 49.9, 50 to 59.9, 60 to 69.9, 70 to 79.9, and 80 years or older, respectively. According to our data, 152,215 (0.3%) and 280,666 (0.5%) HRS/WF IPMNs were expected in the Italian male and female populations, respectively. In the European standard population, the prevalence rates were 0.2% (200 HRS/WF IPMNs per 100,000 residents) and 0.4% (420 HRS/WF IPMNs for 100,000 residents) in the male and female populations, respectively. Univariate and multivariate analyses showed that the only 2 factors related to an increase in the crude prevalence rates of IPMNs were age (P < 0.001) and sex (P < 0.001) ( Table 4 ). The prevalence of IPMNs was significantly increased in females with an odds ratio (OR) of 2.4 (95% CI, 1.8-3.2; P < 0.001) in the 50-to 59.9-year group with respect to the 40-to 49.9-year group (OR, 3.2; 95% CI, 1.7-6.3; P = 0.001). The prevalence was also increased in the 70-to 79.9-year group with respect to the 60-to 69.9-year group (OR, 1.9; 95% CI, 1.3-2.8; P < 0.001). The presence of all oncologic diseases (endometrial, ovarian, urothelial, prostatic, blood, nonepithelial solid abdominal, breast, gastric, colon, rectal, melanoma, lung, and hepatic cancer) did not increase the crude prevalence of IPMNs. In addition, the presence of chronic disorder (liver, small bowel) or liver/renal cystic pathologies was not related to an increase in the prevalence of IPMNs.
DISCUSSION
Several studies [1] [2] [3] [4] [5] have reported that the prevalence of PCLs during cross-sectional imaging studies ranges from 2.1% to 49%. However, these studies had some limitations. First, 3 of 5 of these studies [1] [2] [3] were limited by reporting a "highly selected population." In fact, the patients were referred to the hospital for MRI or CT scan; thus, they had a low probability of being really "healthy" or without yet recognized "pancreatic" disease. Second, even if the studies of Chang et al 4 and Kromrey et al 5 have many advantages (a large cohort of nonhospitalized healthy outpatients, imaging cross-sectional examination with high sensitivity, CT or MRI, prospective design), their limitation was that it is unlikely and costly that an asymptomatic outpatients could be screened using CT or MRI for the presence of PCLs. The present study regarded a nonselected population, and it is the first study that used abdominal US to evaluate the prevalence rate of PCLs and IPMNs in particular. However, the use of abdominal US seems to be reliable because it has already been tested as a first-line examination in previous studies with a sensitivity reaching 92% when abdominal US is focused on the pancreas. 16, 17 In addition, when comparing the standardized rates of PCL prevalence (2.7% and 2.4% in the Italian and the European standard populations, respectively) with those reported by Zanini et al 3 for the small state of San Marino (an independent state within Italy and thus having characteristics similar to the Italian population) using a CT scanned population (2.2%), it appears evident that US sensitivity seems to be similar to that of CT when performed by an expert and dedicated physician.
When analyzing our data, some interesting findings can be noted. First, regarding the primary end point, the ultrasonographic prevalence rate of IPMNs in a nonselected population was 3.5%. Moreover, the IPMN was 93% of all PCLs, similar to those reported by Chang et al. 4 This means that more than a million and a half Italian people and 2257 per 100,000 European residents can be expected to have an incidental IPMN, which was approximately 200-fold the prevalence of pancreatic cancer. These data show that the IPMN prevalence rate is high and quite similar to the prevalence rate of colorectal polyps. However, it seems that only a small number of IPMNs will develop pancreatic cancer. Stratification by age and sex revealed some interesting information. The prevalence rate of IPMNs related to age was approximately 0% until 50 years of age while it increased dramatically in the age group 50 years or older. Standardized prevalence in the Italian population suggested that only 143,843 expected IPMNs of 1,531,264 (<10%) were found in people younger than 50 years. Reinforcing these data is the fact that the multivariate analysis suggested that the odds of finding an IPMN between 50 and 59.9 years of age were 3-fold higher than in those of 40 to 49.9 years of age. However, a second significant increase in prevalence was observed at older than 70 years with an additional almost 2-fold increase in odds with respect to the previous categories. These data seem to suggest that a population older than 50 years has a high risk of developing IPMNs. Sex also seems to influence the prevalence rates: females have an IPMN prevalence rate nearly 2-fold more than males (4.8% vs 2.1%). This means that if an ultrasonographic screening program with these cutoffs was hypothesized, it would be able to detect approximately 96% and 98% of the expected IPMNs in the male population (16,804/391,841 subjects) and female population (26,797/1,163,853 subjects), respectively. Moreover, the probability of detecting the total number of "at risk IPMNs" was very high (100% in both sexes).
Regarding the secondary end points, the crude and standardized prevalence of the IPMNs presenting HRS and WF was approximately 1% (Table 3) . Namely, in the Italian population, there could be 1,531,264 asymptomatic IPMNs of which 432,881 (approximately one third) could potentially have Tis or T1 pancreatic cancer. These statistics are not so different from the prevalence rate of breast cancer in females (1.5%) or colon, rectal (0.3%), and lung cancer (0.1%) in either sex.
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These data reinforced the hypothesis of an ultrasonographic screening program for a nonselected population older than 50 years. Finally, the multivariate analysis did not show any significant correlation of IPMNs with other benign or malignant diseases, thus refuting any association between IPMNs and extrapancreatic neoplasms or chronic diseases as well as between colorectal cancer, renal cancer, thyroid cancer, or chronic inflammatory disease. 19, 20 The present study has some limitations: retrospective design in a single center and the absence of a follow-up. Despite these limitations, the present study suggested some considerations: (1) IPMNs are high-prevalence precancerous ultrasonographic detectable lesions in an asymptomatic nonhospitalized population; (2) age older than 50 years and female sex were the only factors related to an increase in the IPMN prevalence rate, identifying a possible risk category to screen; (3) a hypothetical screening program based on US could permit identifying numerous pancreatic cancers at an early stage. Consider that, in the Italian health care system, abdominal US has a very low cost, less than €45, the exploration of the advantages and costs of a US screening program for patients older than 50 years is a plausible option. However, the high prevalence of potentially benign IPMNs, and their relatively unknown natural history, could produce an increase in health care costs due to expensive follow-up with MRI or CT. Additional large prospective multicenter studies are needed to confirm our results and to explore the possible costeffectiveness of a screening program using ultrasonography.
